Quarter
Charts

Gossamer Bio, Inc.

GOSS

CIK 0001728117 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$14M
↑+47.1% +$4Mvs FY2024 (Q4)
Gross Profit
$14M
↑+47.1% +$4Mvs FY2024 (Q4)

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$79K
investment in PP&E
Stock-based comp (TTM)
$11M
non-cash dilution

Recent performance · 33 quarters

Revenue↑+47.1% +$4M
$14M
Net Income↓-56.5% -$17M
$-48M
Free Cash Flow
$0
Operating Margin↓-11.6pts
-369.4%

Drill down

GOSS Sankey

See Gossamer Bio, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

GOSS Charts

33 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

GOSS Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics